MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies

Dow Jones06-08

By Chris Wack

MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy.

Shares were up 14% to $3.79 in recent trading.

The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp.

The FDA approved imetelstat for rare blood cancers originating in bone marrow.

"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers," said MAIA Chief Executive Vlad Vitoc. "We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC.

MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate its activity in NSCLC. THIO is recognized by telomerase and incorporated into telomeres in cancer cells.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 07, 2024 13:12 ET (17:12 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441009959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-08 01:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2441009959","market":"us","top_or_hot":-1,"title":"MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n   MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy. \n</p>\n<p>\n  Shares were up 14% to $3.79 in recent trading. \n</p>\n<p>\n  The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp. \n</p>\n<p>\n  The FDA approved imetelstat for rare blood cancers originating in bone marrow. \n</p>\n<p>\n  \"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers,\" said MAIA Chief Executive Vlad Vitoc. \"We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC. \n</p>\n<p>\n  MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate its activity in NSCLC. THIO is recognized by telomerase and incorporated into telomeres in cancer cells. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 07, 2024 13:12 ET (17:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMAIA Biotechnology Shares Rise After FDA's Telomerase Inhibitor Approval Shows Viability of Such Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-08 01:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n   MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MAIA","symbol_name":"MAIA Biotechnology Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2441009959","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441009959","pubTimestamp":1717780320,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy.Shares were up 14% to $3.79 in recent trading.The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp.The FDA approved imetelstat for rare blood cancers originating in bone marrow.\"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers,\" said MAIA Chief Executive Vlad Vitoc. \"We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC.MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate it","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MAIA":"MAIA Biotechnology Inc.","BK4139":"生物科技"},"translate_title":"FDA批准端粒酶抑制剂显示此类疗法的可行性后，MAIA Biotechnology股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAIA":1},"content_text":"By Chris Wack \n\n\n \n\n\n   MAIA Biotechnology shares rose after the company said telomere targeting functionality, used by its THIO candidate, was shown to be viable by the Food and Drug Administration's approval of a telomerase inhibitor agent therapy. \n\n\n  Shares were up 14% to $3.79 in recent trading. \n\n\n  The company said the clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions have been validated by the FDA's approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies, or myelodysplastic syndromes, from Geron Corp. \n\n\n  The FDA approved imetelstat for rare blood cancers originating in bone marrow. \n\n\n  \"We have found that telomere targeting as a mechanism of action plays a key role in treating certain cancers,\" said MAIA Chief Executive Vlad Vitoc. \"We are studying this science in our Phase 2 trial of THIO in high-risk non-small cell lung cancer, or NSCLC. \n\n\n  MAIA's lead candidate is THIO, a telomere targeting agent in Phase 2 clinical development to evaluate its activity in NSCLC. THIO is recognized by telomerase and incorporated into telomeres in cancer cells. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 07, 2024 13:12 ET (17:12 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441009959"}